Collagen-containing composition derived from fish cartilage

MYPI2025000104A0Undetermined Publication Date: 2024-01-14LINISE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025000104
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-14
Filing Date
2023-07-14
Publication Date
2024-01-14

AI Technical Summary

Technical Problem

Current methods for extracting collagen from animal tissues are inefficient, particularly for type XI collagen, which is underutilized due to limited industrial production and application compared to type II collagen.

Method used

A method involving the use of fish cartilage as a raw material, utilizing acid protease treatment to solubilize collagen, followed by salt-out precipitation, allowing for the efficient recovery of both type II and type XI collagen, with a preferred mass ratio of 10:1 to 1:10 and a collagen content of at least 30% by mass.

Benefits of technology

This method enables the industrial production of a highly functional collagen material containing type II and type XI collagen, promoting chondrocyte hyaluronic acid production and providing effective cartilage protection, suitable for use in foods, supplements, and medical materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025000104_DRAWING_001
    Figure PI2025000104_DRAWING_001
  • Figure PI2025000104_DRAWING_002
    Figure PI2025000104_DRAWING_002
  • Figure PI2025000104_DRAWING_003
    Figure PI2025000104_DRAWING_003
Patent Text Reader

Abstract

There is provided a technique for effectively using a collagen-containing composition derived from fish cartilage. A cartilage-protecting composition or knee-joint-protecting composition that contains a collagen-containing composition derived from fish cartilage as an active ingredient, the collagen-containing composition containing type II collagen and type XI collagen. The collagen-containing composition preferably has a function for promoting hyaluronic acid production capabilities in cartilage cells. Additionally, the collagen-containing composition is preferably derived from salmon nose cartilage. Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Collagen-containing composition derived from fish cartilage

[0001] The present invention relates to a technique for effectively utilizing a collagen-containing composition derived from fish cartilage.

[0002] Collagen is a protein widely distributed in mammals, birds, fish, and other animals, and functions as a major component of their extracellular matrix. It is said to account for approximately 25-30% of total protein in humans. Its molecular structure consists of three peptide chains with a molecular weight of approximately 100,000, which are joined together by hydrogen bonds to form a triple helix. Furthermore, these triple helix structural units are cross-linked at the telopeptide regions that occupy the ends of the collagen molecule to form higher-order structures such as fibrous and meshwork structures. Approximately 28 types of collagen have been identified in humans, and they are classified by function. For example, type I collagen, the major protein in bone, dermis, tendon, etc., consists of two α1 chains and one α2 chain forming a triple helix structure. This fibrous structure has excellent tensile strength and functions as a structural protein that maintains the shape of the body and organs. Type II collagen, meanwhile, consists of three α1 chains forming a triple helix structure, and is localized in cartilage and functions as a structural protein similar to type I. On the other hand, type III and type V collagen coexist with type I in skin, etc., and type XI collagen coexists with type II in cartilage, etc., and are thought to play an auxiliary role in the formation of collagen fibers suited to each tissue (see Non-Patent Documents 1 and 2). Furthermore, the main molecular species of type XI collagen are thought to be composed of three types of chains, α1, α2, and α3, which form a triple helix structure (Non-Patent Document 3).

[0003] Regarding the use of collagen materials, type I collagen, which accounts for the largest proportion of collagen in animal tissues, is widely used as a raw material for cosmetics, health foods, pharmaceuticals, etc. In recent years, the use of type II collagen materials localized in cartilage has also been increasing, and for example, Non-Patent Document 3 reports that antibody titers against type II collagen are elevated in the blood of patients with rheumatoid arthritis, and that oral administration of undenatured type II collagen is expected to have preventive and therapeutic effects on rheumatoid arthritis due to immune tolerance (Non-Patent Document 4).

[0004] Generally, methods for solubilizing and extracting collagen from animal tissues include heat denaturation, acid / alkali solubilization, and enzyme solubilization. However, heat denaturation unravels the triple helix and denatures it randomly. Furthermore, acid solubilization and alkali solubilization, under normal non-denaturing conditions, only a very small amount is eluted, resulting in poor productivity. On the other hand, it is believed that the use of digestive enzymes such as pepsin can partially decompose only the cross-linked structure, allowing efficient extraction of the triple helix structural unit.

[0005] Regarding a method for preparing a type II collagen material, for example, Patent Document 1 describes the preparation of type II collagen having antigen-antibody reactivity with the serum of rheumatoid arthritis patients by using bovine scapular cartilage as a raw material, removing impurities from the raw material through a predetermined pretreatment using a high-pressure water jet, and then carrying out decalcification and pepsin solubilization treatments.

[0006] Toshiharu Hattori, "Properties and Applications of Animal-Derived Fiber Molecule Collagen," Seni to Kogyo, Vol. 65, No. 12 (2009), pp. 453-461. Toshiharu Hattori, "Collagen - Molecular Assembly and Its Applications," Kobunshi, Vol. 47, June issue (1998), pp. 394-397. Hidekatsu Yoshioka, "Type XI Collagen α1 Chain Gene: Primary Structure of the α1 Chain, Its Gene Expression and Regulatory Mechanism," Connective Tissue, 29 (1997), pp. 39-47. David E. Trentham et al., “Effects of oral administration of type II collagen on rheumatoid arthritis.”, Science 261 (1993) pp1727-1730.

[0007] Japanese Patent Application Laid-Open No. 2001-112419

[0008] However, although various preparation methods have been developed to extract non-denatured type II collagen, which is the major type of cartilage-derived collagen, type XI collagen, which is a minor type of cartilage collagen, has only been prepared and used in small amounts for experiments and research purposes, and has not been used as effectively as type II collagen.

[0009] An object of the present invention is to enable the industrial production of type XI collagen as a material that can be effectively utilized industrially, and to provide a technique for utilizing the same.

[0010] As a result of intensive research to achieve the above-mentioned object, the present inventors discovered that type XI collagen can be efficiently recovered together with type II collagen by using fish cartilage as an extraction raw material and treating it with an acidic protease to solubilize collagen and elute it into a liquid fraction, and then thoroughly salting out the liquid fraction, thereby completing the present invention.

[0011] That is, the present invention provides a composition for cartilage protection containing a collagen-containing composition derived from fish cartilage as an active ingredient, wherein the collagen-containing composition contains type II collagen and type XI collagen.

[0012] The present invention also provides a composition for protecting knee joints, which contains a collagen-containing composition derived from fish cartilage as an active ingredient, wherein the collagen-containing composition contains type II collagen and type XI collagen.

[0013] In the above composition, the collagen-containing composition preferably has the functionality of promoting the ability of chondrocytes to produce hyaluronic acid.

[0014] In the above composition, the collagen-containing composition is preferably prepared so that the mass ratio of the type II collagen to the type XI collagen is 10:1 to 1:10, and the collagen content per solid content is 30 mass% or more.

[0015] In the above composition, the collagen-containing composition is preferably derived from salmon nasal cartilage.

[0016] According to the present invention, it is possible to provide a highly functional collagen material that is useful as a material to be incorporated into foods, supplements, pharmaceuticals, medical materials, etc., by using fish cartilage as an extracted raw material.

[0017] 5(a) is a diagram showing the results of investigating the solubilization rate when collagen is eluted from salmon nasal cartilage raw material by enzymatic treatment with lysopathopepsin in Test Example 1. FIG. 5(a) is a diagram summarizing the values ​​of cartilage weight, collagen content, solubilized amount, solubilization rate, average solubility rate, and its standard deviation for each sample of specimen numbers 1 to 3. FIG. 5(b) is a diagram showing the change in solubilization rate over time, and FIG. 5(c) is a diagram summarizing the values ​​on which the graph is based. FIG. 5(c) is a diagram showing the photograph of a gel when a portion of the salting-out precipitate obtained in Production Example 1 was subjected to SDS-PAGE gel electrophoresis in Test Example 2. 7( a ) is a graph showing the results of ion chromatography analysis of a portion of the salting-out precipitate obtained in Production Example 1 in Test Example 3; FIG. 7( a ) is a graph showing a photograph of a gel obtained by SDS-PAGE gel electrophoresis analysis of each fraction fraction obtained by ion chromatography; FIG. 7( b ) is a graph showing an enlarged photograph of the gel corresponding to fraction number 37 and fraction number 41 in the SDS-PAGE gel electrophoresis; and FIG. 7( c ) is a graph showing an analysis chart of the ion chromatography. 8(a) is a graph showing the results of analyzing the salting-out precipitate, 11% ammonium sulfate precipitate, and 20% ammonium sulfate precipitate obtained in Production Example 1 in Test Example 4. FIG. 8(a) is a graph showing a gel photograph obtained when a portion of the 20% ammonium sulfate precipitate and the salting-out precipitate were subjected to SDS-PAGE gel electrophoresis. FIG. 8(b) is a graph showing the results of determining the collagen content by measuring the hydroxyproline content of the salting-out precipitate, 11% ammonium sulfate precipitate, and 20% ammonium sulfate precipitate by dimethylbenzaldehyde colorimetry and multiplying the result by a conversion factor to collagen content. FIG. 8(b) is a graph showing the results of examining the amount of hyaluronic acid produced by rabbit chondrocytes in Test Example 5. FIG. 8(c) is a graph showing the results of hierarchical analysis of VAS scores in Test Example 6, excluding subjects aged 50 or older who scored 10 or less.10 is a chart showing the results of hierarchical analysis of a questionnaire on 10 repeated movements in Test Example 6, excluding subjects aged 50 or older who did not experience any discomfort during the movements.

[0018] The collagen-containing composition used in the present invention can be prepared using fish cartilage as a collagen source. There are no particular limitations on the type of fish or the part of the cartilage tissue, and examples include salmon nasal cartilage (salmon head), shark cartilage, ray cartilage, and squid cartilage. Salmon nasal cartilage (salmon head) is particularly preferred because it has a high collagen content and is inexpensively available as a part that is usually discarded in the seafood processing industry. For example, in salmon roe processing or fillet processing, the heads are discarded in large quantities from landed salmon, so this can be obtained and the nasal cartilage can be extracted from the heads and used.

[0019] One embodiment of a method for preparing a collagen-containing composition used in the present invention is shown in Figure 1. In this embodiment, a collagen-containing composition containing type II collagen and type XI collagen, which are cartilage-derived collagens, is obtained using fish cartilage as an extraction raw material. That is, the method for preparing the collagen-containing composition includes a step of washing the raw material with an alkaline solvent (shown as "S1" in FIG. 1, hereinafter also referred to as the "alkali washing step"), a step of performing an enzymatic treatment with an acid protease in a dilute acidic solvent on the washed product after the alkaline washing (shown as "S2" in FIG. 1, hereinafter also referred to as the "enzyme treatment step"), a step of performing solid-liquid separation on the enzymatically treated product to recover a collagen-containing liquid portion (shown as "S3" in FIG. 1, hereinafter also referred to as the "collagen-containing liquid portion recovery step"), a step of neutralizing and adjusting the pH of the collagen-containing liquid portion recovered by solid-liquid separation (shown as "S4" in FIG. 1, hereinafter also referred to as the "collagen-containing liquid portion neutralization step"), and a step of salting out the neutralized product after neutralizing and adjusting the pH of the collagen-containing liquid portion (shown as "S5" in FIG. 1, hereinafter also referred to as the "salting out treatment step").

[0020] In the above preparation method, although not particularly limited, it is preferable to use, as the extraction raw material, for example, fish cartilage that has been crushed and made to a uniform particle size. The particle size of the cartilage raw material can be made uniform by, for example, using a meat chopper with a plate having a predetermined hole size (for example, a hole size of about 1.8 to 10 mm), or by crushing the cartilage raw material using a homogenizer, mass colander, or the like. By making the particle size uniform, alkaline washing and collagen elution can be carried out more efficiently. The particle size of the cartilage raw material may typically be in the range of 0.1 mm to 10 mm, 0.5 mm to 5 mm, or 1 mm to 3 mm, for example.

[0021] In the above preparation method, in the alkaline washing step, the fish cartilage, which is the extraction raw material, is washed with an alkaline solvent to remove carbohydrate-based extracellular matrix substances such as proteoglycans, hyaluronic acid, etc. The alkaline solvent used is not particularly limited, but may be an aqueous NaOH solution with a concentration ranging from 0.01 M to 1 M, from 0.05 M to 0.5 M, or from 0.1 M to 0.4 M.

[0022] The alkaline washing treatment is preferably carried out by stirring the fish cartilage raw material in an alkaline solvent for a predetermined period of time, followed by solid-liquid separation. This allows for more effective removal of contaminants such as carbohydrate-based extracellular matrix substances from the fish cartilage raw material. The temperature conditions for stirring for alkaline washing are not particularly limited, but it is preferable to control the temperature at a low temperature. For example, the temperature may be in the range of 0°C to 12°C, 2°C to 10°C, or 4°C to 8°C. The stirring time for alkaline washing is also not particularly limited, but may be, for example, in the range of 30 minutes to 48 hours, 1 hour to 36 hours, or 3 hours to 24 hours. For solid-liquid separation, for example, a sieve or filter cloth with a mesh size of approximately 60 to 100, or a centrifuge may be used.

[0023] In one embodiment, the alkaline washing treatment of the fish cartilage raw material with an alkaline solvent in the alkaline washing step may be performed multiple times (e.g., 2 to 4 times) by stirring for a predetermined time, removing the alkaline solvent by solid-liquid separation, and then adding a new alkaline solvent and repeating the washing. This allows for even more effective removal of contaminants such as carbohydrate-based extracellular matrix substances from the fish cartilage raw material. After the alkaline washing, a water washing treatment may be performed by adding water, stirring for a predetermined time, and then performing solid-liquid separation. This water washing treatment may also be repeated multiple times (e.g., 2 to 4 times). It is also preferable to repeat the water washing treatment until the pH of the washing solution becomes approximately neutral. This prevents the alkali used from affecting subsequent treatments.

[0024] In the above preparation method, the washed product after the alkaline washing step is subjected to an enzymatic treatment with an acidic protease in a dilute acidic solvent to solubilize the collagen. The acidic protease used is not particularly limited, but examples include pepsin. Fungal-derived non-animal pepsin is particularly preferred, as it eliminates the need for animal-derived materials associated with diseases such as mad cow disease and foot-and-mouth disease. Examples of fungal-derived non-animal pepsin include rhizopus pepsin, an acidic protease produced by the mold Rhizopus niveus. The dilute acidic solvent used is not particularly limited, but may be, for example, an aqueous acetic acid solution in a concentration range of 10 mM to 500 mM, 250 mM to 500 mM, or 400 mM to 500 mM. Alternatively, the citric acid solution may be, for example, an aqueous solution of citric acid in the concentration range of 10 mM to 500 mM, 250 mM to 500 mM, or 400 mM to 500 mM, although the pH must be adjusted to the acidic side to achieve conditions suitable for acidic proteases.

[0025] In the above-mentioned enzyme treatment, the preferred pH conditions vary depending on the type of enzyme used and are not generalized, but may be, for example, in the range of pH 1 to 6, may be in the range of pH 2 to 5, or may be in the range of pH 2.5 to 3.5. The preferred temperature conditions during the enzyme treatment vary depending on the type of enzyme used and are not generalized, but are preferably within a range in which collagen does not denature, and may be, for example, in the range of 0°C to 12°C, 2°C to 10°C, or 4°C to 8°C. The treatment time during the enzyme treatment is not particularly limited and may be, for example, in the range of 30 minutes to 48 hours, 1 hour to 36 hours, or 3 hours to 24 hours. When Rhizopus pepsin is used as the acidic protease, the amount of enzyme added is typically 1 / 100 to 1 / 5, in some cases 1 / 50 to 1 / 10, and in some cases 1 / 25 to 1 / 15 of the solid content (dry weight) of the fish cartilage raw material added, and the concentration of the Rhizopus pepsin preparation contained in the dilute acidic solvent is typically 0.001 to 1% by mass, in some cases 0.005 to 0.1% by mass, and in some cases 0.01 to 0.05% by mass.

[0026] In one aspect, the pH in the enzyme treatment step may be adjusted to the acidic side by adding a dilute acidic solvent to the fish cartilage raw material and treating it for a predetermined period of time before adding the acidic protease. This prevents the pH from shifting to the alkaline side during treatment with the acidic protease, which would reduce the efficiency of collagen solubilization. For example, the pH can be adjusted to the acidic side by adding a dilute acidic solvent in an amount 1 to 50 times, sometimes 3 to 20 times, and sometimes 5 to 10 times the amount of the cartilage raw material, and stirring for a predetermined period of time. The temperature conditions for such acidic pH adjustment are not particularly limited, but low-temperature temperature control is preferred. For example, the temperature may be in the range of 0°C to 12°C, 2°C to 10°C, or 4°C to 8°C. The stirring time for acidic pH adjustment is also not particularly limited, but may be, for example, 30 minutes to 48 hours, 1 hour to 36 hours, or 3 hours to 24 hours.

[0027] In the above preparation method, in the collagen-containing liquid fraction recovery step, the enzyme-treated product after the enzyme treatment step is subjected to solid-liquid separation to recover a liquid fraction containing collagen eluted from the fish cartilage raw material. Solid-liquid separation can be performed using, for example, a centrifuge. Then, in the collagen-containing liquid fraction neutralization step, the pH of the recovered liquid fraction is adjusted to near neutral. This neutralization adjustment facilitates the effective recovery of not only the major type II collagen, which is a cartilage-derived collagen, but also the minor type XI collagen, through the subsequent salting-out treatment. Neutralization adjustment can be performed by, but is not limited to, adding, for example, a 0.1 M to 1 M aqueous HCl solution or a 0.1 M to 1 M aqueous NaOH solution to the recovered collagen-containing liquid fraction as appropriate while measuring the pH. The pH is preferably adjusted to a range of 7.5 to 8.5, with a pH of around 8 being particularly preferred.

[0028] In the above preparation method, in the salting-out treatment step, the neutralized product obtained after the collagen-containing liquid neutralization step is salted out, and type II collagen and type XI collagen are recovered as salting-out precipitates. Salting-out can be carried out by a conventional method, specifically by adding a salt such as sodium chloride in a solid form or in a form suitable for salting-out, followed by stirring for a predetermined period of time and solid-liquid separation. The final salt concentration may be, for example, in the range of 2 M to 5 M, 2.5 M to 4.5 M, or even 3 M to 4 M. Particularly preferred is 4 M or higher, particularly around 4.4 M. The temperature conditions during such salting-out are not particularly limited, but temperature management at a low temperature is preferred. For example, the temperature may be in the range of 0°C to 12°C, 2°C to 10°C, or 4°C to 8°C. The stirring time during salting-out is also not particularly limited, but may be, for example, in the range of 30 minutes to 48 hours, 1 hour to 36 hours, or 3 hours to 24 hours. The salted-out precipitate may be recovered by solid-liquid separation, as described above, for example, using a centrifuge.

[0029] The salts can be removed from the salting out precipitate obtained as described above by ultrafiltration, dialysis, or the like. Alternatively, the salts may be prepared as a dry product by vacuum freeze-drying. Methods for removing salts from the salting out precipitate include ultrafiltration using a hollow fiber module, a ceramic filter, a flat membrane filter, or the like, and desalination by filling a dialysis tube and immersing the tube in water.

[0030] The collagen content of the collagen-containing composition containing type II collagen and type XI collagen obtained as described above may be 30% by mass or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 65% by mass or more, 70% by mass or more, 75% by mass or more, 80% by mass or more, 85% by mass or more, 90% by mass or more, or 95% by mass or more, based on the solid content. The mass ratio of type II collagen to type XI collagen may be in the range of 10:1 to 1:10, 8:2 to 2:8, or 7:3 to 3:7. The collagen content can be determined by analyzing the hydroxyproline content of the collagen after acid hydrolysis using amino acid composition analysis or dimethylbenzaldehyde colorimetry, and multiplying the result by a predetermined conversion factor to the collagen content. For example, in the case of salmon collagen, there are 54.3 hydroxyproline (Hyp) residues among 1000 amino acid residues, with a content of 7.92%, and the conversion factor from the amount of Hyp to the amount of collagen is 12.63.

[0031] FIG. 2 shows another embodiment of the method for preparing a collagen-containing composition used in the present invention. In this embodiment, the above-described salting-out product containing type II collagen and type XI collagen undergoes a step of dissolving in 0.5 M acetic acid (denoted by "S6" in FIG. 2 ), followed by a step of treating with ammonium sulfate at a predetermined final concentration (denoted by "S7" in FIG. 2 ). This results in a type II collagen-containing composition enriched in type II collagen as the ammonium sulfate precipitate. While 0.5 M acetic acid is exemplified in the figure as the acid solvent used in the dissolution treatment (S6), the concentration can be appropriately adjusted to a solution pH in the range of 2.6 to 2.8, for example, using 0.4 to 0.6 M acetic acid or 0.4 to 0.6 M citric acid. The ammonium sulfate treatment can be carried out by a conventional method, specifically by adding ammonium sulfate in a solid form or in a form suitable for salting-out, followed by stirring for a predetermined period of time and then solid-liquid separation. The final concentration of ammonium sulfate in the ammonium sulfate treatment (S7) is exemplified as 11 w / v% in the figure, but may be, for example, in the range of 10 w / v% to 13 w / v%, or 10.5 w / v% to 12.5 w / v%. A concentration of around 11 w / v% is particularly preferred. The temperature conditions during such ammonium sulfate treatment are not particularly limited, but may be, for example, in the range of 0°C to 12°C, 2°C to 10°C, or 4°C to 8°C. The stirring time during the ammonium sulfate treatment is also not particularly limited, but may be, for example, in the range of 30 minutes to 48 hours, 1 hour to 36 hours, or 3 hours to 24 hours. The ammonium sulfate precipitate can be recovered by solid-liquid separation, as described above, using, for example, a centrifuge.

[0032] The ammonium sulfate precipitate obtained as described above can be subjected to dialysis using ultrafiltration to remove salts. Alternatively, the precipitate may be subjected to vacuum freeze-drying to prepare a dried product. Examples of methods for removing salts from the ammonium sulfate precipitate include physical desalination by ultrafiltration using a hollow fiber module, a ceramic filter, a flat membrane filter, or the like, and desalination by filling a dialysis tube and immersing the tube in water.

[0033] The collagen-containing composition enriched with type II collagen obtained as described above may have a collagen content of 30% by mass or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 65% by mass or more, 70% by mass or more, 75% by mass or more, 80% by mass or more, 85% by mass or more, 90% by mass or more, or 95% by mass or more, based on the solid content.

[0034] Figure 3 shows another embodiment of the method for preparing a collagen-containing composition used in the present invention. This embodiment involves the steps of dissolving the salting-out product containing type II collagen and type XI collagen described above in 0.5 M acetic acid (shown as "S6" in Figure 3), treating with ammonium sulfate at a predetermined first final concentration (shown as "S7" in Figure 3), recovering the supernatant after the ammonium sulfate treatment (shown as "S8" in Figure 3), and treating with ammonium sulfate at a predetermined second final concentration (shown as "S9" in Figure 3). This results in a type XI collagen-containing composition enriched in type XI collagen as the ammonium sulfate precipitate. As described above, the acid solvent used in the dissolution treatment (S6) is exemplified by 0.5 M acetic acid in the figure. Alternatively, for example, 0.4 to 0.6 M acetic acid or 0.4 to 0.6 M citric acid may be used, with the concentration appropriately adjusted so that the solution pH is in the range of 2.6 to 2.8. The ammonium sulfate treatment can be performed by a conventional method, specifically by adding ammonium sulfate in a solid form or in a form suitable for salting out, followed by stirring for a predetermined period of time and solid-liquid separation. The first final concentration of ammonium sulfate in the ammonium sulfate treatment (S7) may be, for example, in the range of 10 w / v% to 13 w / v%, or 10.5 w / v% to 12.5 w / v%, with a concentration of approximately 11 w / v% being particularly preferred. The second final concentration of ammonium sulfate in the ammonium sulfate treatment may be, for example, in the range of 18 w / v% to 22 w / v%, or 19 w / v% to 21 w / v%, with a concentration of approximately 20 w / v% being particularly preferred. The temperature conditions during such ammonium sulfate treatment are not particularly limited, but may be, for example, in the range of 0°C to 20°C, 2°C to 15°C, or 4°C to 10°C. The stirring time during the ammonium sulfate treatment is also not particularly limited, but may be, for example, in the range of 30 minutes to 48 hours, 1 hour to 36 hours, or 3 hours to 24 hours. The supernatant and precipitate after the ammonium sulfate treatment may be recovered by solid-liquid separation, as described above, using, for example, a centrifuge.

[0035] The ammonium sulfate precipitate obtained as described above can be subjected to dialysis using ultrafiltration to remove salts. Alternatively, the precipitate may be subjected to vacuum freeze-drying to prepare a dried product. Examples of methods for removing salts from the ammonium sulfate precipitate include physical desalination by ultrafiltration using a hollow fiber module, a ceramic filter, a flat membrane filter, or the like, and desalination by filling a dialysis tube and immersing the tube in water.

[0036] The collagen-containing composition enriched with type XI collagen obtained as described above may have a collagen content of 30% by mass or more, 40% by mass or more, 50% by mass or more, 60% by mass or more, 65% by mass or more, 70% by mass or more, 75% by mass or more, 80% by mass or more, 85% by mass or more, 90% by mass or more, or 95% by mass or more, based on the solid content.

[0037] The salting-out precipitate containing type II collagen and type XI collagen, the 11% ammonium sulfate precipitate containing type II collagen, and the 20% ammonium sulfate precipitate containing type XI collagen obtained by the preparation methods described above may be dried using means commonly known to those skilled in the art, such as a vacuum dryer or a spray dryer, or the dried product may be further crushed, pulverized, or the like, and dried to form a powder. In the form of a dried product, moisture is removed, similar to the dried product after lyophilization, so spoilage and the like are prevented, resulting in excellent storage stability. During drying, excipients such as textrin, crystalline cellulose, silica, etc. may be added for formulation purposes.

[0038] For powdering, means such as a pulverizer, mill, or mass coloader, which are generally known to those skilled in the art, can be used. Regarding the particle size after powdering, it is preferable to powderize to such an extent that approximately 90% by mass or more of the total passes through a 30 mesh (opening: 500 μm), and more preferably approximately 90% by mass or more of the total passes through a 60 mesh (opening: 250 μm). Alternatively, it is preferable to powderize to such an extent that approximately 90% by mass or more of the total passes through a screen with a diameter of 0.3 mm or more and 0.75 mm or less.

[0039] The salting out precipitate containing type II collagen and type XI collagen, the 11% ammonium sulfate precipitate containing type II collagen, and the 20% ammonium sulfate precipitate containing type XI collagen obtained by the preparation method described above may be mixed with each other in a desired ratio as appropriate to form a collagen-containing composition for use in the present invention.

[0040] As shown in the examples described below, the fish cartilage-derived collagen-containing composition provided by the present invention has an excellent effect of promoting the hyaluronic acid production ability of chondrocytes. It also has an excellent effect of protecting knee joints. Therefore, it can be made into a functional composition containing this as an active ingredient. For example, a composition for cartilage protection can be provided as a functional composition. For example, a composition for knee joint protection can be provided. In one aspect, the functionality provided by the present invention may be functionality as an articular chondrocyte regeneration promoter, functionality as a chondrocyte proliferation promoter, or functionality as a chondrocyte turnover promoter. Furthermore, the subject may be a healthy individual, and the composition may be intended for healthy individuals aged 50 or over. Furthermore, the composition may be intended for animals such as pet animals.

[0041] In the functional composition provided by the present invention, which contains as an active ingredient the collagen-containing composition derived from fish cartilage, there are no particular limitations on the inclusion of other ingredients in addition to the type II collagen and / or type XI collagen, as long as the intended purpose is not impaired. Examples of other ingredients include vitamin C, imidazole peptides, collagen peptides, salmon ovary skin peptides, and β-hydroxy-β-methylbutyric acid (HMB).

[0042] The functional composition provided by the present invention, which contains the collagen-containing composition derived from fish cartilage as an active ingredient, may be used in any form, but is preferably taken orally. When used as an oral composition, the type II collagen and / or type XI collagen may be used as is, or may be made into a tablet form (tablet, tablet, chewable tablet, orally disintegrating agent), a liquid form (liquid), a syrup form (syrup), a powder form (granules, fine granules), a capsule form (capsules), a soft capsule form (soft capsules), a solid form, a semi-liquid form, a cream form, a paste form, or the like, as needed.

[0043] The intake amount may be appropriately determined depending on the health condition or disease state, purpose, etc. of the human or animal to which it is applied, and is not particularly limited. For example, the daily intake amount may be, for example, 5 mg to 100 mg, 5 mg to 40 mg, 5 mg to 20 mg, 10 mg to 20 mg, or 10 mg to 15 mg in terms of collagen amount. The intake period is preferably 12 weeks or more. The intake period may be, for example, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, 12 weeks, etc., and may be taken continuously or intermittently over these periods.

[0044] The fish cartilage-derived collagen-containing composition provided by the present invention can be used, for example, for foods such as health foods and functional foods, supplements, pharmaceuticals, medical materials, etc., and can be particularly suitably used as a raw material for these. Furthermore, as mentioned above, it can be used not only for humans but also for animals such as pet animals.

[0045] The present invention will be specifically explained below by means of Production Examples and Test Examples, but these Production Examples and Test Examples are not intended to limit the scope of the present invention in any way.

[0046] [Production Example 1] Salmon heads were obtained from a seafood processing plant, and 200 g of raw cartilage was extracted from the heads (equivalent to 8 salmon). The collected raw cartilage was chopped using a meat chopper equipped with a 2.8 mm hole plate to prepare the starting material for extraction. Collagen was extracted from the extraction material prepared above.

[0047] The production flow chart of this production example is shown in Figure 4. Specifically, the product was prepared as follows.

[0048] 2400 mL of 0.1 M NaOH aqueous solution was added to 200 g of the extraction raw material, and the mixture was stirred at 4°C for 24 hours. The mixture was then centrifuged at 10,000 g for 20 minutes to separate the solid and liquid. The solid was then recovered. 2400 mL of water was added, and the mixture was stirred at 4°C. The mixture was then centrifuged at 10,000 g for 20 minutes to separate the solid and liquid. The solid was then recovered. The same procedure was repeated. The pH of the supernatant after the second wash was measured and found to be 11.92. The same water wash was repeated, and the pH at the final wash was 9.47. 2000 mL of 10 mM citric acid aqueous solution was added, and the mixture was stirred at 4°C for 24 hours. The pH of the supernatant was measured and found to be 3.0. Rhizopus pepsin (trade name "Neurase F3G", manufactured by Amano Enzyme Inc.) was added, and the mixture was stirred at 4°C for 48 hours. The pH after the treatment was measured and found to be 3.0. The mixture was centrifuged at 10,000 g for 20 minutes to separate the solid and liquid, and the liquid was recovered. Disodium hydrogen phosphate was added to a final concentration of 20 mM, and the mixture was stirred at 4°C for 1 hour. The pH was adjusted to 8.0 by dropwise addition of 6 M HCl aqueous solution or 6 M NaOH aqueous solution. Powdered NaCl was added to a final concentration of 4.4 M, and the mixture was stirred at 4°C for 24 hours. The mixture was centrifuged at 10,000 g for 20 minutes to separate the solid and liquid, and the solid was recovered as a salting-out precipitate. 1200 mL of 0.5 M acetic acid aqueous solution was added to dissolve the salting-out precipitate. Powdered ammonium sulfate was added to a final concentration of 11% W / V, and the mixture was stirred at 4°C for 24 hours. The mixture was centrifuged at 10,000 g for 20 minutes to separate the solid and liquid, and the solid was recovered as an 11% ammonium sulfate precipitate. The liquid portion was collected as the supernatant. Powdered ammonium sulfate was added to the supernatant to a final concentration of 20% W / V, and the mixture was stirred at 4°C for 24 hours. Solid-liquid separation was performed using a centrifuge at 10,000g for 20 minutes, and the solid portion was collected as a 20% ammonium sulfate precipitate. The mixture was desalted by dialysis. Specifically, the mixture was packed into a dialysis tube with a molecular weight cutoff of 12,000 to 16,000 (Eidia Co., Ltd., Cellulose Tube 36 / 32) and immersed in water for desalting. The mixture was dried using a vacuum freeze dryer.

[0049] Test Example 1 In the production flow of Production Example 1, the solubilization rate of collagen by enzyme treatment with Rhizopus pepsin was examined.

[0050] First, the amount of collagen contained in the salmon nasal cartilage used as the extraction material was measured. Specifically, 30 mg of freeze-dried cartilage was hydrolyzed by adding 5 mL of 6 M HCl (containing 0.04% mercaptoethanol). After freezing and sealing, the cartilage was hydrolyzed at 110°C for 24 hours. The sample was then transferred to an eggplant-shaped flask and the HCl was removed using an evaporator. 5 mL of ultrapure water was added to the sample remaining at the bottom of the eggplant-shaped flask to prepare an analytical sample, and the amount of hydroxyproline (Hyp), a component specific to collagen, was quantified using an automated amino acid analyzer.

[0051] The supernatant after the enzyme treatment in Production Example 1 was collected over time and the collagen content was measured. Specifically, 1 mL of the collected enzyme-treated supernatant was dispensed into a test tube, 1 mL of 12 M HCl was added, the tube was sealed, and hydrolysis was carried out by heating in a hot block bath at 130°C for 3 hours. The sample was transferred to an eggplant-shaped flask, and the hydrochloric acid was removed using an evaporator. 5 mL of ultrapure water was added to the sample remaining at the bottom of the eggplant-shaped flask to prepare an analytical sample, and the content of hydroxyproline (Hyp), which is specific to collagen, was measured by a standard colorimetric method using dimethylbenzaldehyde (J.F. Woesnner Jr., Archives of Biochemistry and Biophysics, 93, 440-447, 1961).

[0052] The hydroxyproline (Hyp) content (g) was converted to collagen content (g) by multiplying it by a coefficient of 12.63.

[0053] As shown in Figure 5(a), all three measurements were performed and the calculated solubilization rate was stable at a high level of over 90%. Furthermore, as shown in Figures 5(b) and 5(c), the solubilization rate over time reached over 90% 24 hours after the start of enzyme treatment.

[0054] Test Example 2 FIG. 6 shows a photograph of a gel obtained when a portion of the salting out precipitate obtained in Production Example 1 was subjected to SDS-PAGE gel electrophoresis.

[0055] As shown in Figure 6, in comparison with the electrophoretic image of the salmon skin collagen sample, the salting-out precipitate from salmon cartilage showed a band at a molecular weight of approximately 116 kDa, which is characteristic of α1 (triple helix chain) of type II collagen, a collagen derived from cartilage. In addition, two bands, α1 and α2, which are thought to be characteristic of type XI collagen, which has a triple helix structure of α1, α2, and α3, were observed at molecular weights of approximately 130 kDa to 160 kDa.

[0056] Test Example 3 FIG. 7 shows the results of ion chromatography analysis of a portion of the salting out precipitate obtained in Production Example 1.

[0057] Specifically, a portion of the salting-out precipitate obtained in Preparation Example 1 was dissolved in 20 mM sodium acetate buffer (pH 4.8) containing 2 M urea and subjected to cation exchange chromatography. An ion exchange column (Showa Denko K.K., CM-825) packed with a packing material having a carboxymethyl group as a ligand was used, and the adsorbed protein was eluted with a 0-0.4 M NaCl gradient (concentration gradient) over 40 minutes at a flow rate of 1.0 mL / min. The eluate was detected by continuously measuring the absorbance at 230 nm, and the eluate was collected using a fraction collector in 1 mL fractions. The column temperature was maintained at 18°C. The resulting peak fractions were subjected to SDS-PAGE gel electrophoresis.

[0058] As shown in Figure 7(a), among the peaks appearing by absorbance at 230 nm for each fraction obtained by ion chromatography in Figure 7(c), components stained with Coomassie Brilliant Blue R-250, a protein stain, appeared from fraction numbers 31 to 42, and bands were observed in all fractions at molecular weights of approximately 116 to 160 kDa. Furthermore, as shown in Figure 7(b), a band thought to be due to the α1 triple chain corresponding to type II collagen appeared in fraction number 37 obtained by ion chromatography, while a band thought to be due to the α1-α3 triple chain corresponding to type XI collagen appeared in fraction number 41.

[0059] Test Example 4 FIG. 8 shows the results of analyzing the salting out precipitate, 11% ammonium sulfate precipitate, and 20% ammonium sulfate precipitate obtained in Production Example 1.

[0060] As shown in the results of SDS-PAGE gel electrophoresis in FIG. 8( a), the 20% ammonium sulfate precipitate obtained in Production Example 1 contained type XI collagen, which appeared in fraction number 41 fractionated by ion chromatography analysis in Test Example 3, and the salting-out precipitate obtained in Production Example 1 contained type II collagen, which appeared in fraction number 37 fractionated by ion chromatography analysis in Test Example 3, and type XI collagen, which appeared in fraction number 41.

[0061] As shown in the results of measuring the collagen amount in FIG. 8( b), the collagen content of the salting out precipitate obtained in Production Example 1 was 67.8% by mass, the collagen content of the 11% ammonium sulfate precipitate was 82.8% by mass, and the collagen content of the 20% ammonium sulfate precipitate was 95.2% by mass.

[0062] Separately, the salting out precipitate obtained in Production Example 1 was subjected to SDS-PAGE gel electrophoresis, and the electrophoretic image was analyzed by protein staining. Type XI collagen was assigned to the α1 chain and α2 chain in descending order of molecular weight, and the remaining α3 chain was contained in a mass ratio of 1:1:1, assuming that the α3 chain overlaps with the α1 chain of type II collagen. Using the staining intensity of the bands corresponding to the α1 chain and α2 chain of type XI collagen having a purity of approximately 95% as an index, a conversion factor was calculated for converting the staining intensity of that band into the amount of collagen. This factor was then stoichiometrically applied to the other bands to perform approximate quantitative measurements. As a result, it was estimated that type II collagen accounted for 60 mass% and type XI collagen for 40 mass% of the collagen contained in the salting out precipitate obtained in Production Example 1.

[0063] Test Example 5 The usefulness of a collagen-containing composition containing type II collagen and type XI collagen was evaluated.

[0064] Specifically, a hyaluronic acid production test was carried out using rabbit chondrocytes as follows.

[0065] [1. Test Substances] Type I collagen (derived from bovine epidermis) (MP Biomedicals, Inc.) Type II collagen (derived from salmon nasal cartilage) (Rinice Co., Ltd.) Type II / type XI collagen [type II: 80% by mass, type XI: 20% by mass] (derived from salmon nasal cartilage) (Rinice Co., Ltd.)

[0066] [2. Cells and Culture Media] Rabbit chondrocytes, female articular cartilage from Japanese white rabbits ("Chondron Cell Culture Kit", Cosmo Bio Co., Ltd.) Culture medium for chondrocyte culture ("Chondron Cell Culture Kit", Cosmo Bio Co., Ltd.) Culture medium for chondrocyte differentiation ("Chondron Cell Culture Kit", Cosmo Bio Co., Ltd.)

[0067] [3. Culturing] The cells obtained in culture were cultured in CO using the culture medium provided with the chondrocyte culture kit. 2 Incubator (5% CO 2The cells were cultured in a chondrocyte differentiation medium (37°C), and the next day, the cells were detached and cryopreserved. Separately, type I collagen, type II collagen, and type II / XI collagen were prepared as test substances at 10 mg / mL each in a chondrocyte differentiation medium, and then filter-sterilized. Each test substance was prepared immediately before addition to the medium. The frozen-thawed cells were awakened in a culture medium and cultured in a T-75 flask. After detaching the cells, 2 x 10 cells were cultured in a differentiation medium containing the test substance. 5 A sample with a cell concentration of 1000 cells / mL was prepared, and the sample was inoculated into a 1.5 mL microtube. 2 in an incubator at 5% CO 2 The cells were cultured under conditions of 1000 μL / tube, 1000 μL / tube, and 37° C. The medium was changed every 2 to 3 days. The culture was continued for 2.5 weeks (17 days), and the final medium change (500 μL / tube) was performed 3 days before the day of collecting the culture supernatant.

[0068] 4. Measurement of Hyaluronic Acid Hyaluronic acid in the culture supernatant was measured using a hyaluronic acid measurement kit (R&D, Cat. No. DY3614) according to the protocol attached to the kit.

[0069] 5. Statistical Analysis A Student T-test was performed to test for significance, and a P value of <0.05 (null hypothesis less than 5%) was determined to indicate a significant difference.

[0070] 6. Results The results are summarized in Table 1 and FIG.

[0071]

[0072] As a result, it was found that the collagen-containing composition containing type II collagen and type XI collagen has the effect of promoting hyaluronic acid production from rabbit chondrocytes. Furthermore, the effect of promoting hyaluronic acid production was more significant than when type I collagen or type II collagen was used.

[0073] Test Example 6 The usefulness of a collagen-containing composition containing type II collagen and type XI collagen was evaluated.

[0074] Specifically, a human test was conducted on healthy individuals as follows.

[0075] [1. Test Foods] Placebo food: A 300 mg tablet made from glucose, fine silicon dioxide, and calcium stearate as a base material. Test food: A placebo tablet containing 10 mg of type II / type XI collagen [type II: 80% by mass, type XI: 20% by mass] (derived from salmon nasal cartilage) (Rinice Co., Ltd.).

[0076] 2. Subjects Volunteers were recruited, and 50 subjects who met the predetermined criteria were randomly assigned to each study group. Table 2 shows the baseline characteristics of the subjects for each study group.

[0077]

[0078] [3. Test Schedule] The subjects were asked to take one tablet of the test food product daily with water or lukewarm water for 16 weeks, without setting a specific intake time.

[0079] [4. Evaluation Items] Knee joint discomfort was evaluated before and after ingestion of the test food. Specifically, a questionnaire using a visual analogue scale (VAS) was administered to assess knee joint pain in five areas (daily, walking, climbing stairs, standing up from a crouch, and standing for a long time) as the primary evaluation item. Additionally, three biomarkers known to indicate knee joint cartilage turnover (serum CPII, a marker of type II collagen synthesis; urinary CTX-II, a marker of type II collagen degradation; and serum C1,2C, a marker of type I and type II collagen degradation) were measured as secondary evaluation items. Biomarker analysis was outsourced to LSI Medience Corporation. Subjects were also asked to perform 10 consecutive crouch-and-stand movements, squats, and stair climbing, and were asked to report the number of times they could perform each movement.

[0080] [5. Statistical analysis] The Wilcoxon signed-rank test was used for intragroup comparisons. The Mann-Whitney U test was used for intergroup comparisons. The significance level was set at 5% on both sides.

[0081] 6. Results The results are summarized in Table 3.

[0082]

[0083] As a result, the following became clear:

[0084] (1) <VAS Score> Evaluation of the VAS questionnaire, the primary endpoint, confirmed a decrease in scores for multiple questions after 16 weeks of intake, and significant differences were also observed in intra-group comparisons. Inter-group comparisons showed a significant difference (P<0.039) in the change in the VAS questionnaire while walking. Regarding other evaluation items, using the results of the VAS questionnaire at rest as a representative example, a decrease in scores was observed in the test group after 16 weeks of intake, but a decrease in scores was also observed in the placebo group, so no significant differences were observed in inter-group comparisons. Figure 10 shows the results of a hierarchical analysis when subjects aged 50 or older who scored 10 or less were excluded. According to this, significant differences (P=0.013) were observed between groups after 16 weeks of intake for VAS scores while walking and ascending and descending stairs. While many subjects under 50 years old had scores of 10 or less, only a few subjects over 50 years old had scores of 10 or less.

[0085] (2) <Articular Cartilage Biomarkers> In the results of the articular cartilage biomarker test, a secondary endpoint, no significant changes were observed between pre- and post-intake in serum CPII, a biomarker for type II collagen synthesis. Furthermore, urinary CTX-II, a biomarker for type II collagen degradation, significantly decreased in the test group, demonstrating a significant difference within the group (P<0.003). However, a trend toward a decrease was also observed in the placebo group, with no significant difference between the two groups. Serum C1 and C2C, markers of type I and type II collagen degradation, also did not change between pre- and post-intake in the test group, demonstrating no significant difference between the two groups. As with the CTX-II results, the CTX-II / CPII ratio significantly decreased in the test group, demonstrating a significant difference within the group (P=0.037). Significant differences were also observed between the two groups.

[0086] (3) <Questionnaire on 10 Repetitive Movements> The results of the questionnaire on 10 repetitive movements, a secondary evaluation item, showed no significant changes in any of the evaluation items between the two groups, and no significant differences were observed between the two groups. Figure 11 shows the results of a hierarchical analysis performed after excluding subjects aged 50 or older who did not experience any discomfort during the movements. According to this, the number of squats performed by the placebo group decreased, while the number of squats performed by the test group increased slightly, demonstrating a significant difference (P = 0.040) between the groups after 16 weeks of intake.

[0087] Based on the above results, it was considered that a collagen-containing composition containing type II collagen and type XI collagen is effective in protecting knee joints.

Claims

1. A composition for cartilage protection containing a collagen-containing composition derived from fish cartilage as an active ingredient, wherein the collagen-containing composition contains type II collagen and type XI collagen.

2. A composition for protecting knee joints, which contains a collagen-containing composition derived from fish cartilage as an active ingredient, wherein the collagen-containing composition contains type II collagen and type XI collagen.

3. The composition according to claim 1 or 2, wherein the collagen-containing composition has the functionality of promoting the ability of chondrocytes to produce hyaluronic acid.

4. The composition according to claim 1 or 2, wherein the collagen-containing composition is prepared so that the mass ratio of the type II collagen to the type XI collagen is 10:1 to 1:10, and the collagen content per solid content is 30 mass% or more.

5. The composition of claim 1 or 2, wherein the collagen-containing composition is derived from salmon nasal cartilage.